Clinical trials: Hospitalized COVID-19
Covid19
COVID-19 Soliris Expanded Access Protocol
This protocol provides participants with COVID-19 access to Soliris.
- Trial name
- NCT04802083
- Testing
- Eculizumab
- Sponsor
- Alexion Pharmaceuticals, Inc.
Covid19
Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19
This is a phase 2 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 (Sotrovimab) Generation 1 (Gen1) or VIR-7831 (Sotrovimab) Generation 2 (Gen2) and will be assessed for safety, tolerability…
- Trial name
- COMET-PEAK (NCT04779879)
- Testing
- Sotrovimab (Gen1), Sotrovimab (Gen2)
- Where
- 31 sites in United States, Canada and 3 more
- Volunteers
- 354 people
- Sponsor
- Vir Biotechnology, Inc.
Coronavirus Disease 2019
Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)
The study will evaluate the safety and efficacy of orally-administered M5049 in Coronavirus disease 2019 (COVID-19) pneumonia participants who are hospitalized but not on mechanical ventilation.
- Trial name
- NCT04448756
- Testing
- M5049
- Where
- 21 sites in United States, Brazil and 1 more
- Volunteers
- 149 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
COVID-19, SARS-CoV-2
Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise
The purpose of this study is to evaluate the efficacy and safety of intravenous abatacept administered to hospitalized COVID-19 participants with respiratory compromise.
- Trial name
- NCT04472494
- Testing
- Abatacept
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 61 people
- Sponsor
- Bristol-Myers Squibb
COVID-19
Recombinant Hyperimmune Polyclonal Antibody (GIGA-2050) in COVID-19 Patients
The purpose of this study is to evaluate the safety and tolerability of single ascending IV dose administrations of GIGA-2050 in patients hospitalized with COVID-19.
- Trial name
- NCT04883138
- Testing
- GIGA-2050
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- GigaGen, Inc.
COVID-19, SARS-CoV-2
Ivermectin to Prevent SARS-CoV-2 (COVID-19) Hospitalisation in Subjects Over 50
The primary objective of this study is to assess the efficacy of early administration of ivermectin for three consecutive days to prevent SARS-CoV-2 hospitalisation in adults older than 50 years of age.
- Trial name
- NCT05993143
- Testing
- Ivermectin
- Where
- 20 sites in Spain
- Volunteers
- 249 people
- Sponsor
- Insud Pharma
Covid19
Risk Stratification and Early Alerting Regarding COVID-19 Hospitalization
The purpose of this research is to remotely monitor individuals who have tested positive for COVID-19 to learn more about progression and recovery from the disease.
- Trial name
- RiskSEARCH (NCT04709068)
- Testing
- Current Health
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Current Health
COVID-19, ARDS, Human
MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients
This study consists of two parts. Part A (Phase I): A Phase I Double-blind Randomized Placebo-controlled Study in Healthy Subjects to Assess the Safety, Pharmacokinetics, Pharmacodynamics of MRG-001 Part B (Phase 2): A Phase IIa…
- Conditions
- COVID-19, ARDS, Human, Stem Cells, Regeneration
- Trial name
- NCT04646603
- Testing
- MRG-001
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- MedRegen LLC
Covid19, Respiratory Disease
Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19
This is a two-arm, randomized, open label, two-center, controlled study to evaluate the safety and efficacy of Viusid plus Asbrip in patients with mild and moderate symptoms of respiratory illness caused by Coronavirus 2019…
- Conditions
- Covid19, Respiratory Disease, Immune System, Immunomodulator
- Trial name
- NCT04701502
- Testing
- Viusid, Asbrip, Standard Care
- Where
- 2 sites in Bulgaria
- Volunteers
- 60 people
- Sponsor
- Catalysis SL
COVID-19
Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)
The purpose of the study is to determine if Liquid Alpha1-Proteinase Inhibitor (Human) (Liquid Alpha1-PI) plus SMT can reduce the proportion of participants dying or requiring intensive care unit (ICU) admission on or before Day…
- Trial name
- NCT04547140
- Testing
- Liquid Alpha1-Proteinase Inhibitor (Human), Standard Medical Treatment
- Where
- 20 sites in United States, Brazil and 3 more
- Volunteers
- 57 people
- Sponsor
- Grifols Therapeutics LLC
Coronavirus Disease 2019, Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
Study of Varespladib in Patients Hospitalized With Severe COVID-19
This is a 2-part, multi-center, randomized, double-blind, placebo-controlled, phase 2 study designed to evaluate the safety, tolerability, and efficacy of oral varespladib, in addition to standard of care, in patients…
- Trial name
- STAIRS (NCT04969991)
- Testing
- Varespladib
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Ophirex, Inc.
COVID-19 Pneumonia
Adding Colchicine to Tocilizumab in Patients With Severe COVID-19 Pneumonia.
Colchicine acts upstream in the cytokines cascade by inhibiting the NLRP3 inflammasome while IL-6 receptor antagonists (tocilizumab) block the end result of the cytokines cascade.
- Trial name
- NCT05118737
- Testing
- Colchicine
- Where
- Qatar
- Volunteers
- 230 people
- Sponsor
- Hamad Medical Corporation
COVID-19
Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy
The study is designed as a multicenter, randomized, double-blind, placebo-controlled, parallel group study of the safety and efficacy of tofacitinib in hospitalized adult participants with COVID-19 pneumonia who are receiving SoC…
- Trial name
- NCT04412252
- Testing
- Tofacitinib
- Where
- 6 sites in United States
- Sponsor
- Pfizer
Covid19
Evaluation of Safety and Tolerability of COR-101 in Hospitalized Patients With Moderate to Severe COVID-19
Primary objectives Part 1: To evaluate the safety and tolerability of COR-101 compared to placebo Secondary objectives Part 1: To evaluate the preliminary efficacy of COR-101 compared to placebo in hospitalized patients with…
- Trial name
- NCT04674566
- Testing
- COR-101
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- Corat Therapeutics Gmbh
Covid19
Novaferon in Non-hospitalized Adult Patients With Mild COVID-19
An Adaptive, Multicenter, Randomized, Double-blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Aerosolized JH509 vs. Placebo in Non-hospitalized Adult Patients with Mild COVID-19
- Trial name
- NCT05172037
- Testing
- Novaferon
- Where
- Japan
- Volunteers
- 222 people
- Sponsor
- Genova Inc.
Severe Acute Respiratory Syndrome Coronavirus 2
Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients
This trial is designed to determine if the inflammation modulating effect of vagus nerve stimulation can improve pulmonary function and limit progression to ARDS in hospitalized COVID-19 hospitalized patients.
- Trial name
- NCT04379037
- Testing
- Transcutaneous Auricular Vagus Nerve Stimulation
- Where
- Argentina
- Volunteers
- 50 people
- Sponsor
- Nemechek Technologies
Covid19, SARS-CoV-2 Infection
Safety, Tolerability and Efficacy Of S-1226 in Moderate Severity Covid-19 Bronchiolitis/Pneumonia
This is a randomized, open-label, controlled, Phase II proof of concept study to evaluate the safety, tolerability and efficacy of S-1226 in which hospitalized subjects (n≤30) with moderate severity COVID-19…
- Trial name
- NCT04738136
- Testing
- S-1226
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- SolAeroMed Inc.
Pneumonia, Viral
Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.
The study objective is to assess Efficacy and safety of Reparixin treatment as compared to placebo (both on top of standard treatment) in adult patients with severe COVID-19 pneumonia.
- Trial name
- NCT04878055
- Testing
- Reparixin
- Where
- 17 sites in United States, Italy
- Volunteers
- 287 people
- Sponsor
- Dompé Farmaceutici S.p.A
Viral Disease
First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.
It is Phase 1b, 2-part, double-blind, placebo-controlled study to evaluate safety, tolerability, and pharmacokinetics of PF-07304814, in patients hospitalized with SARS-CoV-2 virus infection.
- Trial name
- NCT04535167
- Testing
- PF-07304814
- Where
- 13 sites in United States, Belgium and 2 more
- Volunteers
- 26 people
- Sponsor
- Pfizer
COVID-19 Infection
Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection
Treatment of patients hospitalised for management of moderate COVID-19 infection
- Trial name
- Neptuno (NCT04784559)
- Testing
- Plitidepsin, Dexamethasone, Remdesivir
- Where
- 28 sites in Brazil, Bulgaria and 6 more
- Volunteers
- 205 people
- Sponsor
- PharmaMar